ClinicalTrials.gg
CompletedNCT02910388Updated Jun 2, 2020

LLETZ Under Direct Colposcopic Vision

An interventional study of LLETZ with colposcopy and LLETZ without colposcopy in Uterine Cervical Dysplasia, sponsored by Zydolab - Institute of Cytology and Immune Cytochemistry. Completed at 1 site in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-02.

Sponsored by Zydolab - Institute of Cytology and Immune Cytochemistry · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

To assess the benefits of large Loop excision of the transformation Zone (LLETZ) under direct colposcopic Vision.

02

Conditions studied

  • Uterine Cervical Dysplasia

Keywords

  • conization
  • LLETZ
  • loop excision
  • randomized controlled trial
  • colposcopy
  • direct colposcopic vision
  • intraoperative colposcopy
03

In context

Uterine Cervical Dysplasia

409 studies on the registry are indexed under Uterine Cervical Dysplasia; 76 are open to participants now.

This study's enrollment of 150 is below the median of 167 across 285 interventional studies indexed under Uterine Cervical Dysplasia.

Browse Uterine Cervical Dysplasia studies →

Lead sponsor

Zydolab - Institute of Cytology and Immune Cytochemistry is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven cervical dysplasia
  • colposcopy Prior to conization

Exclusion criteria

Exclusion Criteria:

  • significant language barrier
  • a personal history of conization
  • pregnancy
  • the use of blood thinner
  • unwillingness to participate
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    LLETZ with colposcopy

    The LLETZ procedure will be performed under direct colposcopic vision

    Device: LLETZ with colposcopy

  • Active comparator
    LLETZ without colposcopy

    The LLETZ procedure will be performed without colposcopy

    Other: LLETZ without colposcopy

Interventions

  • DeviceLLETZ with colposcopy

    Loop procedure using a colposcope in order to see and remove the abnormal cervical tissue

  • OtherLLETZ without colposcopy

    Loop procedure without using a colposcope

06

What researchers measure

Primary outcomes

  1. the resected cone mass

    the resected cone mass will be quantified by weighing the removed tissue with a precision scale located in the operating room

    Time frame: 10 minutes

Secondary outcomes

  1. Margin status

    Resection margin is judge as "R0" if abnormal cells are not found in the margin of the biopsy or "R1" if abnormal cells remain in the margin of the biopsy. The histopathological examination will be done by an Independent pathologist

    Time frame: 2 Days after conization

  2. Operation time

    the time from the beginning of the Operation (start of the electrosurgical method) until the end of the operation (the end of hemostatic interventions) will be measured in minutes

    Time frame: 20 minutes

  3. Operative complications

    Operative complications defined as necessity to intervene therapeutically up to 14 days postoperatively

    Time frame: 14 days

  4. number of fragments of the surgical specimen

    surgeons will count the number of the surgical specimen (1 vs. \>1)

    Time frame: 10 minutes

  5. the dimensions of the surgical specimens

    The circumference, length and thickness of The surgical specimens will be measured

    Time frame: 2 Days after conization

  6. handling of the device

    surgeons will score their preference regarding the surgical method using an 11-step visual analogue scale (VAS) for ,(ranging from 0 (,very easy') to 10 (,very difficult')

    Time frame: 30 minutes

  7. satisfaction with the device

    surgeons will score their preference regarding the surgical method using an 11-step visual analogue scale (VAS) for ,satisfaction with the device' (ranging from 0 (,very satisfied') to 10 (,absolutely not satisfied')

    Time frame: 30 minutes

  8. Time to complete intraoperative hemostasis

    the time until complete hemostasis as judged by the surgeon has been achieved, will be measured in seconds

    Time frame: 120 seconds

  9. Intraoperative blood loss

    intraoperative blood loss will be measured using the difference in serum hemoglobin one day prior to surgery and within 5 hours postoperatively

    Time frame: 5 hours

07

Study locations

1 site
  • Department of Obstetrics and Gynecology of the Ruhr University Bochum
    Herne, NRW 44625, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02910388
Lead sponsor
Zydolab - Institute of Cytology and Immune Cytochemistry
Responsible party
Sponsor
First posted
Sep 22, 2016
Start date
Oct 2016
Primary completion
Dec 2017
Completion
Dec 2017
Last update
Jun 2, 2020

Study contacts

Ziad Hilal, M.D.
principal investigator · Zydolab - Institute of Cytology and Immune Cytochemistry

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion